Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9NWF9

UPID:
RN216_HUMAN

ALTERNATIVE NAMES:
RING finger protein 216; RING-type E3 ubiquitin transferase RNF216; Triad domain-containing protein 3; Ubiquitin-conjugating enzyme 7-interacting protein 1; Zinc finger protein inhibiting NF-kappa-B

ALTERNATIVE UPACC:
Q9NWF9; Q6Y691; Q75ML7; Q7Z2H7; Q7Z7C1; Q8NHW7; Q9NYT1

BACKGROUND:
The protein E3 ubiquitin-protein ligase RNF216 functions as an E3 ubiquitin ligase, facilitating the transfer of ubiquitin to substrates, thereby targeting them for proteasomal degradation. It regulates antiviral responses and inflammation by modulating the degradation of TRAF3, TLR4, and TLR9, and affects NF-kappa-B and IRF3 activation.

THERAPEUTIC SIGNIFICANCE:
Linked to Gordon Holmes syndrome, RNF216's involvement in neurodegenerative and hormonal disorders underscores its importance in drug discovery. Understanding the role of E3 ubiquitin-protein ligase RNF216 could open doors to potential therapeutic strategies for related conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.